Download:
pdf |
pdfPublic Site: Page Survey Steps (select yes)
Was This Page Helpful
Was This Page Helpfu l? -
displays at the bottom ►
Ill
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
of the page.
What can we do to improve this page?
When the user selects
"Yes" they get an
opportunity to offer
suggestions to
►
/,
improve the page.
Previous
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
We thank you for your time taking this survey.
Your response has been recorded.
A brief thank you and
the survey disclaimer
appear when the user
presses the "Finish"
button.
►
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
Burden Disclosure
Public reporting burden for this collection of information is estimated to average 2 minutes per
response, including the time for reviewing instructions, searching existing data sources,
gathering and maintaining the data needed, and completing and reviewing the collection of
information. An agency may not conduct or sponsor, and a person is not required to respond to,
a collection of information unless it displays a currently valid OMB control number. Send
comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705
Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA# 0925-0668. Do not return
the completed form to this address.
Public Site: Page Survey Steps (select no)
Was This Page Helpful
displays at the bottom
►
Was This Page Help ful? -
Ill
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
of the page.
I did not find this page helpful because the content on the page
(check all that apply):
Had too little information
,........, Had too much information
If a user selects "No"
they are asked to
select one or more
►
reasons why.
Was confusing
,........, Was out-of-date
Other
Previous
Ill
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
What can we do to improve this page?
When the user selects
"Next " they get an
opportunity to offer
suggestions to
►
/,
improve the page.
Previous
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
A brief thank you and
the burden disclosure
appear when the user
presses the "Finish"
button.
►
We thank you for your time taking this survey.
Your response has been recorded.
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
Burden Disclosure
Public reporting burden for this collection of information is estimated to average 2 minutes per
response, including the time for reviewing instructions, searching existing data sources,
gathering and maintaining the data needed, and completing and reviewing the collection of
information. An agency may not conduct or sponsor, and a person is not required to respond to,
a collection of information unless it displays a currently valid OMB control number. Send
comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705
Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA# 0925-0668. Do not return
the completed form to this address.
Search NIAID Q.
Search
RESEARCH
I DISEASES & CONDITIONS I
GRANTS & CONTRACTS
I
CLINICAL TRIALS
I NEWS & EVENTS I ABOUT NIAID
Share This:
News & Events > Newsroom > News Releases
I
Newsroom
000
Essential Malaria Parasite Genes Revealed
News Releases
Media Contacts
NIAID-Funded Research Could Aid Antimalarial Drug Development
Dr. Fauci in the News
May 3, 2018
NIAID-Funded Research
News
Researchers have exploited a quirk in the genetic make-up of the
deadly malaria parasite, Plasmodium falciparum, to create
38,000 mutant strains and then determine which of the
organism's genes are essential to its growth and survival. P.
falciparum is responsible for about half of all malaria cases and
90 percent of all malaria deaths. New information about the
parasite's critical gene repertoire could help investigators
prioritize targets for future antimalarial drug development.
The international research team led by John H. Adams, Ph.D., of
the University of South Florida, was supported by the National
Institute of Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health. The study appears in the May 4
issue of Science. Rays H.Y. Jiang, Ph.D., of Universtiy of South
Florida, and Julian C. Rayner, Ph.D., of the Wellcome Trust
Sanger Institute, U.K., collaborated with Dr. Adams in this
research.
Congressional Testimony
The complete genetic sequence of P. falciparum was deter•
mined more than a decade ago, but the functions of most
of its genes remain unknown, a n d until now only a few hundred
mutant strains had been created in the lab. The difficulties in
manipulating P. falciparum stem in part from the extremely high
percentage of adenine or thymine (two of the four chemical
building blocks that make up DNA) in its genome. Standard
methods for creating mutants rely on more variation in gene
sequences and so do not work on P. falciparum. In the new
research, Dr. Adams and his colleagues created mutated
versions of nearly all the parasite's 6,000 genes with a technique
that preferentially targets areas rich in adenine and thymine,
thus exploiting the very feature that had foiled previous attempts at
Colorized scanning electron micrograph of red blood cell
infected wi th malaria paras ites, w hich are colorized in b lue.
The infected cell is in the center of the image area. To the
are uninfected cells with a smooth red surface.
Credit: NIAID
genetic manipulation.
Was this page helpful?
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
CONTACT US
PUBLICATIONS
HELP
ARCHIVE
Connect with NIAID
f
m
•
'# 1n
@
8• E,
'P Ea
SITE MAP
INFORMACl6N EN ESPANOL
EMPLOYEE INFORMATION
Website Policies & Notices
Related Government Websites
Freedom of Information Act(FOIA).
National Institutes of Health 13'
Health and Human ServicesC?
N o Fear Act Data
PrivacY.PolicY.
USA.govC?
Search NIAID Q.
Search
RESEARCH
I DISEASES & CONDITIONS I
GRANTS & CONTRACTS
I CLINICAL TRIALS I NEWS & EVENTS I ABOUT NIAID
Share This:
News & Events > Newsroom > News Releases
I
Newsroom
000
Essential Malaria Parasite Genes Revealed
News Releases
Media Contacts
NIAID-Funded Research Could Aid Antimalarial Drug Development
Dr. Fauci in the News
May 3, 2018
NIAID-Funded Research
News
Researchers have exploited a quirk in the genetic make-up of the
deadly malaria parasite, Plasmodium falciparum, to create
38,000 mutant strains and then determine which of the
organism's genes are essential to its growth and survival. P.
falciparum is responsible for about half of all malaria cases and
90 percent of all malaria deaths. New information about the
parasite's critical gene repertoire could help investigators
prioritize targets for future antimalarial drug development.
The international research team led by John H. Adams, Ph.D., of
the University of South Florida, was supported by the National
Institute of Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health.The study appears in the May 4
issue of Science. Rays H.Y. Jiang, Ph.D., of Universtiy of South
Florida, and Julian C. Rayner, Ph.D., of the Wellcome Trust
Sanger Institute, U.K., collaborated with Dr. Adams in this
research.
Congressional Testimony
The complete genetic sequence of P. falciparum was deter•
mined more than a decade ago, but the functions of most
of its genes remain unknown, a n d until now only a few hundred
mutant strains had been created in the lab. The difficulties in
manipulating P. falciparum stem in part from the extremely high
percentage of adenine or thymine (two of the four chemical
building blocks that make up DNA) in its genome. Standard
methods for creating mutants rely on more variation in gene
sequences and so do not work on P. falciparum. In the new
Colorized scanning el ectron micrograph of red blood cell
infected wi th malaria paras ites, w h ich are colorized in b lue.
The infected cell is in the center of the image area. To the
are uninfected cells with a smooth red surface.
Credit: NIAID
research, Dr. Adams and his colleagues created mutated
versions of nearly all the parasite's 6,000 genes with a technique
that preferentially targets areas rich in adenine and thymine,
thus exploiting the very feature that had foiled previous attempts at genetic manipulation.
We thank you for your time taking this survey.
Your response hasbeen recorded.
Form approved OMB#: 0925-0668, EXP. DATE: 02/28/2019
Burden Disclosure
Public reporting burden for this collection of information is estimated to average 2 minutes per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of
information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a
currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including
suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN:
PRA# 0925-0668. Do not return the completed form to this address.
CONTACT US
PUBLICATIONS
HELP
ARCHIVE
Connect with NIAID
•
f '# 1n g+
...
""
r.,
,;:-::,
..
l!O
SITE MAP
INFORMAC16N EN ESPANOL
EMPLOYEE INFORMATION
Website Policies & Notices
Related Government Websites
Freedom o f Information Act(FOIA)
.
No Fear Act Data
PrivacY. PoliCY.
National Institutes o f Health 8"
Health and Human Services 8"
USA.g.QY8"
File Type | application/pdf |
File Modified | 2018-09-04 |
File Created | 2018-08-28 |